Top Markets
#1 Black Phoenix Black Phoenix +355.83%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +56.22%
#4 Akedo Akedo +47.65%
#5 Acurast Acurast +37.50%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.68%
#7 BasedHype BasedHype +26.37%
#8 Cryptopia Cryptopia +21.54%
#9 Avantis Avantis +21.14%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +15.55%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Immatics biotechnologies GmbH Immatics biotechnologies GmbH

Immatics biotechnologies GmbH

IMTXW
Rank in Stocks #40870
Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to... Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T cell-redirecting immunotherapies designed to combat cancer, primarily targeting the United States market for treatment applications. Their research and development efforts are concentrated on creating targeted immunotherapies for solid tumors, employing two distinct therapeutic strategies: adoptive cell therapies (ACTs) and antibody-like T-cell receptor (TCR) Bispecifics. Immatics N.V. boasts a robust pipeline of product candidates. Among these are IMA203, an immunotherapy targeting solid tumors, and IMA203CD8, a cell therapy product, both currently undergoing Phase 1b clinical trials. Additionally, their earlier-stage assets include IMA204, designed to target tumor stroma, and IMA30x, an allogeneic cellular therapy candidate, both of which are in preclinical development. The company is also progressing with its TCR Bispecifics portfolio, featuring IMA401 in Phase 1b clinical trials, alongside IMA402 and IMA403, which are presently in preclinical phases. Furthermore, Immatics N.V. has established strategic alliances to bolster its development efforts. These include a partnership with MD Anderson Cancer Center for the advancement of various T cell and TCR-based adoptive cellular therapies, an agreement with Celgene Corporation focused on creating innovative adoptive cell therapies for diverse cancers, and a collaboration with Genmab A/S aimed at developing T cell-engaging bispecific immunotherapies for multiple oncological indications. The company's corporate headquarters are situated in Tübingen, Germany.
Share Price
$0.0006
Last synced: 2025-06-30
Market Cap
$69.91K
Change (1 day)
-88.46%
Change (1 year)
0.00%
Country
US
Trade Immatics biotechnologies GmbH (IMTXW)

Category

Healthcare
Stock price history for Immatics biotechnologies GmbH (IMTXW)
Highest end of day price: $0.01 on 2025-06-01

Lowest end of day price: $3.85 on 2020-07-01
Stock price history of Immatics biotechnologies GmbH from 2020 to 2026
Annual Stock Price Performance
Year Performance
2025 -95.05%
2024 -89.61%
2023 3.46%
2022 -27.40%
2021 31.37%
2020 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $522.05 31.86%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $863.30 33.51%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $744.96 8.94%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.08K -6.68%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $259.89 16.65%
BE